Avita Medical (RCEL) to Release Earnings on Thursday

Avita Medical (NASDAQ:RCEL) is expected to be posting its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect Avita Medical to post earnings of ($0.35) per share and revenue of $18.2960 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.

Avita Medical Trading Up 6.3%

Shares of NASDAQ RCEL opened at $4.37 on Tuesday. Avita Medical has a 1-year low of $3.22 and a 1-year high of $7.43. The company has a market cap of $134.51 million, a PE ratio of -2.50 and a beta of 1.90. The company has a 50-day moving average of $4.43 and a two-hundred day moving average of $4.05.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Avita Medical in a research note on Wednesday, April 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avita Medical in a research note on Friday, March 27th. Lake Street Capital boosted their target price on shares of Avita Medical from $3.00 to $3.50 and gave the stock a “hold” rating in a research note on Friday, January 16th. Wall Street Zen downgraded shares of Avita Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 2nd. Finally, Northland Securities assumed coverage on shares of Avita Medical in a research note on Thursday, March 5th. They issued an “outperform” rating and a $10.00 target price for the company. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.63.

Institutional Investors Weigh In On Avita Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Deutsche Bank AG raised its stake in shares of Avita Medical by 1,351.5% during the fourth quarter. Deutsche Bank AG now owns 7,896 shares of the company’s stock worth $27,000 after buying an additional 7,352 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Avita Medical by 122.2% during the fourth quarter. Russell Investments Group Ltd. now owns 8,047 shares of the company’s stock worth $28,000 after buying an additional 4,425 shares during the last quarter. Aristides Capital LLC bought a new stake in shares of Avita Medical during the fourth quarter worth approximately $48,000. The Manufacturers Life Insurance Company bought a new stake in shares of Avita Medical during the second quarter worth approximately $58,000. Finally, Wells Fargo & Company MN raised its stake in shares of Avita Medical by 98.5% during the fourth quarter. Wells Fargo & Company MN now owns 18,832 shares of the company’s stock worth $65,000 after buying an additional 9,345 shares during the last quarter. 27.66% of the stock is owned by institutional investors.

Avita Medical Company Profile

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.